{
  "abstract": "Tarang Sharma and colleagues argue for increased collaboration across public and private sectors—internationally and with patients—in drug assessment and managed entry agreements to support equitable and sustainable access to costly medicines",
  "authors": [
    {
      "affiliations": [
        "Access to Medicines and Health Products, World Health Organization Regional Office for Europe, Copenhagen, Denmark"
      ],
      "name": "Tarang Sharma"
    },
    {
      "affiliations": [
        "Evidence Link, Ontario, Canada"
      ],
      "name": "Krista Kruja"
    },
    {
      "affiliations": [
        "Norwegian Institute of Public Health, Oslo, Norway"
      ],
      "name": "Christine Årdal"
    },
    {
      "affiliations": [
        "LWC Health, Canberra, Australia",
        "Faculty of Pharmacy, University of Strasbourg, Strasbourg, France"
      ],
      "name": "Ruth Lopert"
    },
    {
      "affiliations": [
        "Department of Economics, University Carlos III, Madrid, Spain"
      ],
      "name": "Jorge Mestre-Ferrandiz"
    },
    {
      "affiliations": [
        "Patient representative, SG REFORM, European Commission, Brussels, Belgium"
      ],
      "name": "Simone Boselli"
    },
    {
      "affiliations": [
        "WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies, Pharmacoeconomics Department, Gesundheit Österreich, Vienna, Austria",
        "Department of Health Care Management, Technische Universität Berlin, Berlin, Germany"
      ],
      "name": "Sabine Vogler"
    }
  ],
  "title": "Managing costly new drugs to support equitable access: international collaboration and patient engagement to assess value, and managed entry agreements",
  "uid": "d5d79a7c-a364-52e8-89a2-8a2b98028319"
}